The DOI matches its Crossref record; 290 of the 290 references it cites were found in a registry or an index.
Therapeutic targeting of the hypoxic tumour microenvironment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–290 of 290
Repopulation of γ-irradiated Lewis lung carcinoma by malignant cells and host macrophage progenitors
Stephens, T. C., Currie, G. A., & Peacock, J. H. (1978) · British Journal of Cancer · doi:10.1038/bjc.1978.252 · Cited by 94
Salem, A., Little, R. A., Latif, A., Featherstone, A. K., Babur, M., Peset, I., Cheung, S., Watson, Y., Tessyman, V., Mistry, H. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3932 · Cited by 92
Dhani, N. C., Serra, S., Pintilie, M., Schwock, J., Xu, J., Gallinger, S., Hill, R. P., & Hedley, D. W. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.284 · Cited by 89
Hypoxic cell sensitizers for radiotherapy
ADAMS, G. E. (1978) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(78)90129-3 · Cited by 88
Hypoxia-active nanoparticles used in tumor theranostic
Wang, Y., Shang, W., Niu, M., Tian, J., & Xu, K. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s196959 · Cited by 87
Estrada‐Bernal, A., Le, A. T., Doak, A. E., Tirunagaru, V. G., Silva, S., Bull, M. R., Smaill, J. B., Patterson, A. V., Kim, C., Liu, S. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3555 · Cited by 86
Liu, S. V., Villaruz, L. C., Lee, V. H.-F., Zhu, V. W., Baik, C. S., Sacher, A. G., McCoach, C. E., Nguyen, D., Li, J. Y.-C., Pacheco, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2294 · Cited by 85
Hunter, F. W., Young, R. J., Shalev, Z., Vellanki, R. N., Wang, J., Gu, Y., Joshi, N., Sreebhavan, S., Weinreb, I., Goldstein, D. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1107 · Cited by 82
Self-citationDesign, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs
O'Connor, L. J., Cázares-Körner, C., Saha, J., Evans, C. N. G., Stratford, M. R. L., Hammond, E. M., & Conway, S. J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.034 · Cited by 82
D’Anna, F., Dyck, L. V., Xiong, J., Zhao, H., Berrens, R. V., Qian, J., Bieniasz-Krzywiec, P., Chandra, V., Schoonjans, L., Matthews, J. B., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02087-z · Cited by 78
Wilson, W. R., Hicks, K. O., Pullen, S. M., Ferry, D. M., Helsby, N. A., & Patterson, A. V. (2007) · Radiation Research · doi:10.1667/rr0807.1 · Cited by 75
Self-citationHicks, K. O., Myint, H., Patterson, A. V., Pruijn, F. B., Siim, B. G., Patel, K., & Wilson, W. R. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.049 · Cited by 74
Self-citationDiflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia
Guise, C. P., Abbattista, M. R., Tipparaju, S. R., Lambie, N., Su, J., Li, D., Wilson, W. R., Dachs, G. U., & Patterson, A. V. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073759 · Cited by 74
Self-citationBodo, S., Campagne, C., Thin, T. H., Higginson, D. S., Vargas, H. A., Hua, G., Fuller, J. D., Ackerstaff, E., Russell, J., Zhang, Z., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97631 · Cited by 74
Jaiswal, A. R., Liu, A. J., Pudakalakatti, S., Dutta, P., Jayaprakash, P., Bartkowiak, T., Ager, C. R., Wang, Z., Reuben, A., Cooper, Z. A., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0005 · Cited by 74
Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy
Hatfield, S. M., & Sitkovsky, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137554 · Cited by 73
Cázares-Körner, C., Pires, I. M., Swallow, I. D., Grayer, S. C., O’Connor, L. J., Olcina, M. M., Christlieb, M., Conway, S. J., & Hammond, E. M. (2013) · ACS Chemical Biology · doi:10.1021/cb4001537 · Cited by 73
Cutsem, E. V., Lenz, H., Furuse, J., Tabernero, J. M., Heinemann, V., Ioka, T., Bazin, I. S., Ueno, M., Csőszi, T., Wasan, H. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4007 · Cited by 73
Wang, J., Foehrenbacher, A., Su, J., Patel, R., Hay, M. P., Hicks, K. O., & Wilson, W. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2296 · Cited by 69
Self-citationGu, Y., Patterson, A. V., Atwell, G. J., Chernikova, S. B., Brown, J. M., Thompson, L. H., & Wilson, W. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1209 · Cited by 69
Self-citationLatimer, H. R., & Veal, E. A. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2327 · Cited by 68
pH-Selective Cytotoxicity of pHLIP-Antimicrobial Peptide Conjugates
Burns, K. E., McCleerey, T. P., & Thévenin, D. (2016) · Scientific Reports · doi:10.1038/srep28465 · Cited by 68
Zschaeck, S., Löck, S., Hofheinz, F., Zips, D., Mortensen, L. S., Zöphel, K., Troost, E. G. C., Boeke, S., Saksø, M., Mönnich, D., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.05.022 · Cited by 67
Wei, H., Duan, Y., Gou, W., Cui, J., Ning, H., Li, D., Qin, Y. W., Liu, Q., & Li, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.055 · Cited by 62
Hegde, A. M., Jayaprakash, P., Couillault, C., Piha-Paul, S. A., Karp, D. D., Rodon, J. A., Pant, S., Fu, S., Dumbrava, E. E. I., Yap, T. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4118 · Cited by 62
New ways to image and target tumour hypoxia and its molecular responses
Dubois, L. J., Niemans, R., van Kuijk, S. J. A., Panth, K. M., Parvathaneni, N.-K., Peeters, S. G. J. A., Zegers, C. M. L., Rekers, N. H., van Gisbergen, M. W., Biemans, R., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.08.022 · Cited by 60
Koritzinsky, M., & Wouters, B. G. (2013) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.05.006 · Cited by 56
Czochor, J. R., Sulkowski, P. L., & Glazer, P. M. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0399 · Cited by 56
Tris –base buffer: a promising new inhibitor for cancer progression and metastasis
Ibrahim‐Hashim, A., Abrahams, D. F., Enríquez‐Navas, P. M., Luddy, K. A., Gatenby, R. A., & Gillies, R. J. (2017) · Cancer Medicine · doi:10.1002/cam4.1032 · Cited by 56
Iikuni, S., Ono, M., Watanabe, H., Shimizu, Y., Sano, K., & Saji, H. (2018) · Theranostics · doi:10.7150/thno.20982 · Cited by 56
A Dynamic Equilibrium between CDKs and PP2A Modulates Phosphorylation of pRB, p107 and p130
Garriga, J., Jayaraman, A. L., Limón, A., Jayadeva, G., Sotillo, E., Truongcao, M. M., Patsialou, A., Wadzinski, B. E., & Graña, X. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1183 · Cited by 55
Liu, J. F., Brady, M. F., Matulonis, U. A., Miller, A., Kohn, E. C., Swisher, E. M., Tew, W. P., Cloven, N. G., Muller, C. Y., Bender, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.6003 · Cited by 55
Karasawa, K., Sunamura, M., Okamoto, A., Nemoto, K., Matsuno, S., Nishimura, Y., & Shibamoto, Y. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.02.007 · Cited by 52
Bacigalupa, Z. A., & Rathmell, W. K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.034 · Cited by 50
Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers
Price, C. O., Gill, S., Ho, Z. V., Davidson, S. M., Merkel, E., McFarland, J. M., Leung, L., Tang, A., Kost‐Alimova, M., Tsherniak, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2674 · Cited by 49
Koike, N., Kota, R., Naito, Y., Hayakawa, N., Matsuura, T., Hishiki, T., Onishi, N., Fukada, J., Suematsu, M., Shigematsu, N., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01165-z · Cited by 49
Neumeister, V. M., Sullivan, C. A. W., Lindner, R. M., Lezon-Geyda, K., Li, J., Závada, J., Martel, M., Glazer, P. M., Tuck, D. P., Rimm, D. L., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2232-0 · Cited by 48
Maeda, A., Chen, Y., Bu, J., Mujčić, H., Wouters, B. G., & DaCosta, R. S. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.09.005 · Cited by 48
Radiation Damage to Tumor Vasculature Initiates a Program That Promotes Tumor Recurrences
Brown, J. M. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.028 · Cited by 48
Hunter, F. W., Hsu, H., Su, J., Pullen, S. M., Wilson, W. R., & Wang, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0476 · Cited by 46
Self-citationHicks, K. O., Siim, B. G., Pruijn, F. B., & Wilson, W. R. (2004) · Radiation Research · doi:10.1667/rr3178 · Cited by 46
Self-citationTrinkaus, M., Hicks, R. J., Young, R. J., Peters, L. J., Solomon, B., Bressel, M., Corry, J. F., Fisher, R., Binns, D., McArthur, G. A., et al. (2014) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12155 · Cited by 44
Haffty, B. G., Son, Y. H., Wilson, L. D., Papac, R. J., FISCHER, D. B., Rockwell, S., Sartorelli, A. C., Ross, D. A., Sasaki, C. T., & Fischer, J. J. (1997) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1997)5:5<213::aid-roi1>3.0.co;2-0 · Cited by 44
McGowan, D. R., Skwarski, M., Bradley, K. M., Campo, L., Fenwick, J. D., Gleeson, F. V., Green, M., Horne, A., Maughan, T., McCole, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.03.015 · Cited by 43
Catalani, E., Buonanno, F., Lupidi, G., Bongiorni, S., Belardi, R., Zecchini, S., Giovarelli, M., Coazzoli, M., Palma, C. D., Perrotta, C., et al. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00463 · Cited by 42
Thomas, L. W., Esposito, C., Morgan, R., Price, S., Young, J., Williams, S. P., Maddalena, L. A., McDermott, U., & Ashcroft, M. A. (2021) · Communications Biology · doi:10.1038/s42003-021-02098-x · Cited by 42
Lecavalier‐Barsoum, M., Chaudary, N., Han, K. C.-Z., Pintilie, M., Hill, R. P., & Milosevic, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0497-3 · Cited by 41
Clinical Efficacy of Olaparib in IDH1/IDH2- Mutant Mesenchymal Sarcomas
Eder, J. P., Doroshow, D. B., Do, K. T., Keedy, V. L., Sklar, J., Glazer, P. M., Bindra, R. S., & Shapiro, G. I. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00247 · Cited by 41
Wang, J., Guise, C. P., Dachs, G. U., Phung, Y., Hsu, A., Lambie, N., Patterson, A. V., & Wilson, W. R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.003 · Cited by 40
Self-citationRischin, D., Fisher, R., Peters, L., Corry, J. F., & Hicks, R. J. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.043 · Cited by 40
Shinde, S. S., Anderson, R. F., Hay, M. P., Gamage, S. A., & Denny, W. A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja048740l · Cited by 39
Graves, E. E., Hicks, R. J., Binns, D., Bressel, M., Le, Q., Peters, L., Young, R. J., & Rischin, D. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3247-7 · Cited by 39
Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs
Jackson, R. K., Liew, L. P., & Hay, M. P. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.02.004 · Cited by 39
Bailey, S. M., Lewis, A. D., Patterson, L. H., Fisher, G. R., Knox, R. J., & Workman, P. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00674-8 · Cited by 38
Shrieve, D. C., & Harris, J. (1985) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553008514551131 · Cited by 38
Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor
Skwarska, A., Calder, E. D. D., Sneddon, D., Bolland, H. R., Odyniec, M. L., Mistry, I. N., Martin, J., Folkes, L. K., Conway, S. J., & Hammond, E. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.004 · Cited by 38
Mehibel, M., Xu, Y., Li, C. G., Moon, E. J., Thakkar, K. N., Diep, A. N., Kim, R. K., Bloomstein, J. D., Xiao, Y., Bacal, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146256 · Cited by 38
Tercel, M., Lee, H. H., Mehta, S. Y., Youte, J., Bai, S. Y., Liyanage, H. D. S., & Pruijn, F. B. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00563 · Cited by 37
Lost in application: Measuring hypoxia for radiotherapy optimisation
Thiruthaneeswaran, N., Bibby, B. A. S., Yang, L., Hoskin, P., Bristow, R. G., Choudhury, A., & West, C. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.039 · Cited by 37
SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase
Bueno, M. T. D., & Richard, S. (2013) · Epigenetics · doi:10.4161/epi.26112 · Cited by 35
Helleday, T. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.02.044 · Cited by 34
Yang, W.-S., Campbell, M., & Chang, P. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006216 · Cited by 34
Löck, S., Linge, A., Seidlitz, A., Bandurska‐Luque, A., Nowak, A., Gudziol, V., Buchholz, F., Aust, D. E., Baretton, G. B., Zöphel, K., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.02.020 · Cited by 34
Study of SHMT2 Inhibitors and Their Binding Mechanism by Computational Alanine Scanning
He, L., Bao, J., Yang, Y., Dong, S., Zhang, L., Qi, Y., & Zhang, J. Z. H. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00370 · Cited by 34
Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects
Hong, C. R., Dickson, B. D., Jaiswal, J. K., Pruijn, F. B., Hunter, F. W., Hay, M. P., Hicks, K. O., & Wilson, W. R. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.027 · Cited by 33
Self-citationHong, C. R., Bogle, G., Wang, J., Patel, K., Pruijn, F. B., Wilson, W. R., & Hicks, K. O. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01013 · Cited by 33
Self-citationDachs, G. U., Gandhi, J., Wohlrab, C., Carr, A. C., Morrin, H. R., Pullar, J. M., Bayer, S. B., Eglinton, T., Robinson, B. A., & Vissers, M. C. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600715 · Cited by 33
Horan, A. D., & Koch, C. J. (2001) · Radiation Research · doi:10.1667/0033-7587(2001)156[0388:tkmfro]2.0.co;2 · Cited by 32
Jongen, J. M. J., van der Waals, L. M., Trumpi, K., Laoukili, J., Peters, N. A., van Schelven, S. J., Govaert, K. M., Rinkes, I. H. M. B., & Kranenburg, O. (2017) · Oncotarget · doi:10.18632/oncotarget.21145 · Cited by 32
Reduced CTL motility and activity in avascular tumor areas
Manaster, Y., Shipony, Z., Hutzler, A., Kolesnikov, M., Avivi, C., Shalmon, B., Barshack, I., Besser, M. J., Feferman, T., & Shakhar, G. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02361-5 · Cited by 30
Tumor hypermetabolism confers resistance to immunotherapy
Liu, A. J., & Curran, M. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.009 · Cited by 29
Saksø, M., Mortensen, L. S., Primdahl, H., Johansen, J., Kallehauge, J. F., Hansen, C. R., & Overgaard, J. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.08.006 · Cited by 29
Hong, C. R., Wilson, W. R., & Hicks, K. O. (2018) · Neoplasia · doi:10.1016/j.neo.2018.11.009 · Cited by 28
Self-citationWong, W. W., Jackson, R. K., Liew, L. P., Dickson, B. D., Cheng, G. J., Lipert, B. A., Gu, Y., Hunter, F. W., Wilson, W. R., & Hay, M. P. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113641 · Cited by 28
Self-citationHunter, F. W., Jaiswal, J. K., Hurley, D., Liyanage, H. D. S., McManaway, S. P., Gu, Y., Richter, S., Wang, J., Tercel, M., Print, C. G., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.03.001 · Cited by 27
Self-citationWinn, B. A., Devkota, L., Kuch, B., MacDonough, M. T., Strecker, T. E., Wang, Y., Shi, Z., Gerberich, J., Mondal, D., Ramirez, A. J., et al. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00773 · Cited by 27
Su, J., Gu, Y., Pruijn, F. B., Smaill, J. B., Patterson, A. V., Guise, C. P., & Wilson, W. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.505222 · Cited by 26
Self-citationLindquist, K. E., Cran, J., Kordic, K., Chua, P. C., Winters, G. C., Tan, J. S., Lozada, J., Kyle, A. H., Evans, J., & Minchinton, A. I. (2013) · Tumor Microenvironment and Therapy · doi:10.2478/tumor-2013-0003 · Cited by 23
Hypoxia-activated pro-drugs of the KDAC inhibitor vorinostat (SAHA)
Calder, E. D. D., Skwarska, A., Sneddon, D., Folkes, L. K., Mistry, I. N., Conway, S. J., & Hammond, E. M. (2020) · Tetrahedron · doi:10.1016/j.tet.2020.131170 · Cited by 22
Hypoxia-inducible factor-1 mediates the expression of DNA polymerase ι in human tumor cells
Ito, A., Koshikawa, N., Mochizuki, S., Omura, K., & Takenaga, K. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.048 · Cited by 21
Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
Dickson, B. D., Wong, W. W., Wilson, W. R., & Hay, M. P. (2019) · Molecules · doi:10.3390/molecules24081559 · Cited by 21
Self-citationWong, H. S., Mezera, V., Dighe, P. A., Melov, S., Gerencser, A. A., Sweis, R. F., Pliushchev, M. A., Wang, Z., Esbenshade, T. A., McKibben, B. P., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.447 · Cited by 21
Intratumoral heterogeneity and hypoxia gene expression signatures: Is a single biopsy adequate?
Lukovic, J., Han, K. C.-Z., Pintilie, M., Chaudary, N., Hill, R. P., Fyles, A., & Milosevic, M. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.09.006 · Cited by 20
Hunter, F. W., Devaux, J. B. L., Meng, F., Hong, C. R., Khan, A., Tsai, P., Ketela, T. W., Sharma, I., Kakadia, P. M., Marastoni, S., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.115196 · Cited by 18
Self-citationA Strategy for Selective O6‐Alkylguanine‐DNA Alkyltransferase Depletion Under Hypoxic Conditions
Penketh, P. G., Shyam, K., Baumann, R. P., Ishiguro, K., Patridge, E. V., Zhu, R., & Sartorelli, A. C. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01401.x · Cited by 16
Role of hypoxia-activated prodrugs in combination with radiation therapy: An in silico approach
Meaney, C., Powathil, G., Yaromina, A., Dubois, L. J., Lambin, P., & Kohande, M. (2019) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2019312 · Cited by 13
Henley, M. J., Doyle, S. K., & Koehler, A. N. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.014 · Cited by 11
Non-heme dioxygenases in tumor hypoxia: They’re all bound with the same fate
Anindya, R. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.12.001 · Cited by 9
Guise, C. P., Abbattista, M. R., Anderson, R. F., Li, D., Taghipouran, R., Tsai, A., Lee, S. J., Smaill, J. B., Denny, W. A., Hay, M. P., et al. (2020) · Molecules · doi:10.3390/molecules25214888 · Cited by 7
Self-citationYu, S. E., Park, S. H., & Jang, Y. K. (2018) · Animal Cells and Systems · doi:10.1080/19768354.2018.1426628 · Cited by 2
Cited by
Targeting immunogenic cell stress and death for cancer therapy
Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 538
Cancer cell metabolism and antitumour immunity
De Martino, M., Rathmell, J. C., Galluzzi, L., & Vanpouille-Box, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01026-4 · Cited by 327
Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics
Wei, D., Sun, Y., Zhu, H., & Fu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.3c06019 · Cited by 303
Bai, R., Li, Y., Jian, L., Yang, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 279
Tumor hypoxia: From basic knowledge to therapeutic implications
Liao, C., Liu, X., Zhang, C., & Zhang, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.011 · Cited by 223
Metadata
- Authors
- Singleton, D. C., Macann, A., & Wilson, W. R.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-07-29
- Volume
- 18
- Issue
- 12
- Pages
- 751-772
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3183577372
- Cited by
- 484
- References
- 290
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.